News

Public · Published

Wells Fargo maintains BioNTech at Overweight, lowers price target to $125 from $140

Wells Fargo kept its Overweight rating on BioNTech but lowered its price target to $125 from $140, a 10.7% decrease. The new target implies 43.8% upside from BioNTech's Nov. 3 closing price of $86.92.

Published:

Updated:

What happened

Wells Fargo kept its Overweight rating on BioNTech but lowered its price target to $125 from $140, a 10.7% decrease. The new target implies 43.8% upside from BioNTech’s Nov. 3 closing price of $86.92.

Confirmed

Global impact / market context

The lower target signals that Wells Fargo now sees less potential value for BioNTech than before, even while keeping its favorable rating. If other analysts also reduce expectations, investors could become less willing to buy or hold the shares, potentially affecting the company’s ability to raise capital through stock sales.

Analyst inference

The three most recent analyst notes cited, published over 30 days, show targets from $110 to $132, placing Wells Fargo’s $125 target within that range. This spread reflects differing analyst estimates, not a guaranteed share price or a confirmed change in BioNTech’s business results.

Confirmed

What to watch

  1. Check whether BioNTech reports business or financial results that explain the lower target; the supplied article gives no reason for Wells Fargo’s change. Analyst inference
  2. Compare future analyst targets with the cited $110–$132 range to see whether estimates are being revised up or down. Analyst inference
  3. Watch whether BioNTech’s share price moves toward or away from Wells Fargo’s $125 target; the article reports no subsequent price movement. Analyst inference

Evidence

  • Original source link unavailable